Compositions and methods for enhanced fluorine-19 magnetic resonance imaging cell tracking
Compositions and methods for enhanced fluorine-19 magnetic resonance imaging cell tracking
批准号:
9893716
负责人:
ERIC T. AHRENS
金额:
$53.75万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-15 至 2022-02-28
关键词:
AdoptionAnimal ModelBiologicalCancer ModelCancer PatientCell CountCell TherapyCell physiologyCellsCellular immunotherapyChelating AgentsClinicalClinical InvestigatorClinical TrialsDendritic CellsDetectionDiseaseDoseElementsEyeFeedbackFluorineFluorocarbonsFormulationFutureGrowthHot SpotImageImaging technologyImmuneImmunotherapeutic agentInflammationInjectionsIonsIronLabelLaboratoriesLeukocytesLifeMagnetic Resonance ImagingMagnetismMalignant NeoplasmsMeasuresMetalsMethodsModelingMolecularNatureNoiseOilsPatientsPeptidesPhasePhysiologic pulsePopulationPreclinical TestingPropertyRelaxationResearch PersonnelRouteSamplingSchemeScienceScientistSignal TransductionSiteSolid NeoplasmSpeedT-LymphocyteTechnologyTherapeuticTimeWorkbasecancer immunotherapeuticscancer immunotherapycell behaviorcell motilitycell typecellular imagingchelationchimeric antigen receptorclinical translationcytotoxicitydata acquisitiondesignexperienceimaging detectionimaging modalityimaging probeimaging propertiesimprovedin vivoin vivo imaginginnovationinterestintravenous injectionmacrophagemagnetic fieldmanufacturing scale-upmolecular imagingnanoemulsionnew technologynovelnovel therapeuticspre-clinicalpreventstem cellssurfactanttraffickingtumoruptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
A common need for clinical developers of cell therapies, such as immunotherapeutic and stem cells, is a non-
invasive means to visualize the fate of cells following injection. Imaging of cell trafficking can provide critical
feedback regarding the persistence, motility, optimal routes of delivery and therapeutic doses. This project aims
to synthesize and biologically evaluate innovative new imaging probes for sensitive in vivo cell tracking using
fluorine-19 (19F) magnetic resonance imaging (MRI). We will advance the formulation science of a compelling
new class of ‘metallo-perfluorocarbon’ (MPFC) nanoemulsion imaging probes. These agents will be a key
element to a multi-pronged strategy to advance cell detection sensitivity by an order of magnitude over current
19F MRI cell detection technologies. Overall, in 19F cell tracking, cell populations of interest are initially labeled in
culture using perfluorocarbon nanoemulsions. Following transfer to the subject, cells are tracked in vivo using
19F MRI. The fluorine inside the cells yields cell-specific images, with no background signal. One of the
bottlenecks preventing the broader adoption of 19F based cell tracking is sensitivity limits to sparse cell numbers.
The sensitivity of this technology can be improved by a three-pronged approach: (1) molecular design and
synthesis to improve the intrinsic sensitivity of the molecular signal generator and (2) nanoemulsion probe
formulation with cell targeting to enhance intracellular delivery and uptake, and (3) employing MRI data
acquisition schemes that have a more efficient signal-to-noise ratio per acquisition time (SNR/t). Recent results
have demonstrated dramatically-enhanced sensitivity of fluorine MRI by molecular design. We have created a
new class of molecules that combine highly fluorinated nanoemulsions with the magnetic properties of metals
that are solubilized into the fluorous phase. Solubilized paramagnetic metal ions provide a dramatic reduction in
the 19F spin-lattice relaxation time thereby enhancing SNR/t and cell detection sensitivity. It was discovered that
iron is most effective metal at enhancing the fluorine MRI signal. Building on these preliminary results, the
proposal has four Specific Aims: Aim 1. Chelation strategies for MPFCs. We will evaluate a range of suitable
chelate molecules and synthesis strategies to stably incorporate metal ions into PFC. Aim 2. Enhanced cell
delivery of MPFC nanoemulsion using cell penetrating peptides (CPPs). Successful MRI detection of cells
critically requires optimal intracellular delivery of emulsified MPFC ex vivo. We will develop novel MPFC
nanoemulsion formulations incorporating CPPs attached to the nanoemulsion surfactant to rapidly and optimally
label cells for cell tracking. Aim 3. “Smart” in vivo targeted nanoemulsions. As an exploratory extension of this
work, we devise MPFC nanoemulsions that target tumors in vivo. Aim 4. In vivo imaging methods to track
immunotherapeutic T cells in cancer. To evaluate new MPFC nanoemulsion probes, we will label T cells and
deliver these to immunotherapeutic cancer models. To image these models, sparse sampling MRI acquisition
methods (e.g., compressed sensing) will be implemented and optimized for MPFC agents to maximize SNR/t.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metallo-fluorocarbon nanoemulsion for PET detection of cancer inflammation
-
批准号:10737153
-
项目类别:
-
资助金额:$65.57万
-
财政年份:2023
-
负责人:ERIC T. AHRENS
-
依托单位:
Intracellular oxygen sensing using 19F MRI
-
批准号:8919703
-
项目类别:
-
资助金额:$33.0万
-
财政年份:2013
-
负责人:ERIC T. AHRENS
-
依托单位:
Intracellular oxygen sensing using 19F MRI
-
批准号:8562847
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2013
-
负责人:ERIC T. AHRENS
-
依托单位:
Intracellular oxygen sensing using 19F MRI
-
批准号:8720000
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2013
-
负责人:ERIC T. AHRENS
-
依托单位:
Platform for myocardial infarct MRI and delivery of therapeutics
-
批准号:8395201
-
项目类别:
-
资助金额:$37.92万
-
财政年份:2012
-
负责人:ERIC T. AHRENS
-
依托单位:
IN VIVO VISUALIZATION AND QUANTIFICATION OF EPIGENETIC ACTIVITIES USING MAGNETIC
-
批准号:8145600
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2010
-
负责人:ERIC T. AHRENS
-
依托单位:
IN VIVO VISUALIZATION AND QUANTIFICATION OF EPIGENETIC ACTIVITIES USING MAGNETIC
-
批准号:8141909
-
项目类别:
-
资助金额:$30.56万
-
财政年份:2010
-
负责人:ERIC T. AHRENS
-
依托单位:
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS
-
批准号:8250461
-
项目类别:
-
资助金额:$42.48万
-
财政年份:2009
-
负责人:ERIC T. AHRENS
-
依托单位:
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS
-
批准号:7663569
-
项目类别:
-
资助金额:$49.21万
-
财政年份:2009
-
负责人:ERIC T. AHRENS
-
依托单位:
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
-
批准号:10225356
-
项目类别:
-
资助金额:$45.99万
-
财政年份:2009
-
负责人:ERIC T. AHRENS
-
依托单位:
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
-
批准号:9384692
-
项目类别:
-
资助金额:$54.05万
-
财政年份:2009
-
负责人:ERIC T. AHRENS
-
依托单位:
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
-
批准号:9980334
-
项目类别:
-
资助金额:$50.11万
-
财政年份:2009
-
负责人:ERIC T. AHRENS
-
依托单位:
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS
-
批准号:8192912
-
项目类别:
-
资助金额:$49.21万
-
财政年份:2009
-
负责人:ERIC T. AHRENS
-
依托单位:
IMAGING CORE
-
批准号:7716549
-
项目类别:
-
资助金额:$62.33万
-
财政年份:2008
-
负责人:ERIC T. AHRENS
-
依托单位:
19F MRI PROBES AND AUTOIMMUNE DISEASE
-
批准号:6869179
-
项目类别:
-
资助金额:$30.49万
-
财政年份:2005
-
负责人:ERIC T. AHRENS
-
依托单位:
NOVEL MARKERS FOR IMAGING GENE EXPRESSION IN VIVO USING MRI
-
批准号:7120551
-
项目类别:
-
资助金额:$32.09万
-
财政年份:2005
-
负责人:ERIC T. AHRENS
-
依托单位:
19F MRI probes and autoimmune disease
-
批准号:7171883
-
项目类别:
-
资助金额:$27.8万
-
财政年份:2005
-
负责人:ERIC T. AHRENS
-
依托单位:
19 FMRI PROBES AND AUTOIMMUNE DISEASE
-
批准号:7009899
-
项目类别:
-
资助金额:$28.63万
-
财政年份:2005
-
负责人:ERIC T. AHRENS
-
依托单位:
19F MRI probes and autoimmune disease
-
批准号:7367810
-
项目类别:
-
资助金额:$27.67万
-
财政年份:2005
-
负责人:ERIC T. AHRENS
-
依托单位:
NOVEL MARKERS FOR IMAGING GENE EXPRESSION IN VIVO USING MRI
-
批准号:7252431
-
项目类别:
-
资助金额:$31.16万
-
财政年份:2005
-
负责人:ERIC T. AHRENS
-
依托单位:
海外基金